| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Prodcut name | Zanamivir Hydrate |
| Synonyms | Relenza;5-acetamido-4-guanidino-2,3,4,5-tetradeoxy-D-glycero-D-galacto-non-2-enopyranosonic acid;Zanamivir Hydrate;4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid 4-Guanidino-Neu5Ac2en; |
| MOQ | 1kg |
| CAS | 139110-80-8 |
| Appearance | Powder |
| Molecular Formula | C12H20N4O7 |
| Molecular Weight | 332.31 |
| Assay | 99% |
| Application | Pharma grade |
| Packing | As per your request |
| Storage | Preserve in tight, light-resistant containers in a cool place |
| Remarks | NA |
| Custom synthesis | Available |
1.Product Name:Zanamivir powder
2.Specification:99%
3.Appearance:White to Colorless Crystalline Powder
4.Test Method:HPLC
5.Grade:Pharmaceutical Grade
6.Description:
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses.
Zanamivir was launched as Relenza in Australia for treatment of human influenza A and B virus infections. Zanamivir (4-guanidino-Neu5Ac2en) can be obtained by several similar ways, for instance in seven step synthesis starting from N-acetyI-D-neuraminic acid. Mechanistically, Zanamivir is a potent and specific inhibitor of neuraminidase (or sialidase), a key viral surface glycohydrolase essential for viral replication and disease progression by catalyzing the cleavage of terminal sialic acid residues from the glycoprotein. The in vitro activity of Zanamivir against a wide variety of influenza A and B strains was demonstrated in different model systems; its activity against clinically relevant isolates of influenza virus, with IC50 values ranging from 0.005 to 15 pM was superior to those of amantadine and rimantadine.
It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.
){kind=link}